低剂量超声造影联合血清microRNA-1469水平在肝脏肿瘤良恶性诊断中的应用

于慧娟; 邢丽丽; 杨帆; 李广明

doi:10.16766/j.cnki.issn.1674-4152.002823

低剂量超声造影联合血清microRNA-1469水平在肝脏肿瘤良恶性诊断中的应用

doi: 10.16766/j.cnki.issn.1674-4152.002823

1.
郑州市第七人民医院超声医学影像科, 河南郑州 450000
2.
郑州市第六人民医院肝病五科, 河南郑州 450000

基金项目:

河南省医学科技攻关项目 2018020849

详细信息

通讯作者:
于慧娟，E-mail：lcx110_xcl@163.com

中图分类号: R730.41 R735.7
计量
- 文章访问数: 262
- HTML全文浏览量: 102
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-11
- 网络出版日期: 2023-04-07

Low-dose contrast-enhanced ultrasound combined with serum microRNA-1469 level in the diagnosis of benign and malignant liver tumours

1.
Department of Ultrasound Medical Imaging, the Seventh People' s Hospital of Zhengzhou, Zhengzhou, Henan 450000, China

摘要

摘要: 目的分析肝脏良性恶肿瘤诊断中低剂量超声造影与血清微小RNA-1469联合使用的价值。方法回顾性分析2017年1月—2020年1月在郑州市第七人民医院就诊的103例肝脏肿瘤患者的临床资料，按照肿瘤良恶性分为良性肿瘤组(50例)与恶性肿瘤组(53例)。所有患者于入院时进行低剂量超声造影检查，并检测血清miR-1469水平，评价低剂量超声造影联合血清miR-1469对肝脏肿瘤良恶性的诊断价值。结果良性肿瘤组超声造影的峰值强度[(127.84±14.59)dB]低于恶性肿瘤组[(186.36±18.14)dB，P＜0.05]，超声造影的达峰时间[(60.28±6.52)s]高于恶性肿瘤组[(40.75±4.87)s，P＜0.05]，血清miR-1469表达量(5.74±0.62)高于恶性肿瘤组(0.82±0.08，P＜0.05)。ROC曲线分析显示，超声造影峰值强度和达峰时间分别以155.32 dB、42.34 s为最佳截断点，诊断肝脏恶性肿瘤的AUC分别为0.791、0.801，达峰时间的AUC更高；miR-1469诊断肝脏恶性肿瘤的最佳截断点为0.88；超声造影与miR-1469联合诊断的灵敏度、AUC、约登指数分别为74.46%、0.912和0.640。结论低剂量超声造影联合血清miR-1469可用于诊断肝脏肿瘤良恶性，诊断效能优于单独诊断，临床应用价值较高。
- 超声造影 /
- 微小RNA-1469 /
- 肝脏肿瘤 /
- 诊断
Abstract: Objective To analyze the value of low dose contrast-enhanced ultrasound combined with serum microRNA-1469 in the diagnosis of benign and malignant neoplasms in liver. Methods A retrospective analysis of the clinical data of 103 patients with liver tumours who were admitted from January 2017 to January 2020 in Seventh People' s Hospital of Zhengzhou was conducted. According to benign and malignant tumors, they were divided into benign tumor group (50 cases) and malignant tumor group (53 cases). Low-dose contrast-enhanced ultrasonography was performed at admission, and the level of serum miR-1469 was detected. The value of low-dose contrast-enhanced ultrasound combined with serum miR-1469 in the diagnosis of benign and malignant liver tumours was evaluated. Results The peak intensity of contrast-enhanced ultrasound in the benign tumour group [(127.84±14.59) dB] was lower than that in the malignant tumour group [(186.36±18.14) dB, P < 0.05]. In the benign tumour group, the peak time of contrast-enhanced ultrasound [(60.28±6.52) s] was higher than that in the malignant tumour group [(40.75±4.87) s, P < 0.05], and the expression level of miR-1469 (5.74±0.62) was higher than that of the malignant tumour group (0.82±0.08, P < 0.05). ROC analysis showed that the peak intensity and peak time of contrast-enhanced ultrasound were 155.32 dB and 42.34 s, respectively. The area under the curve (AUC) of liver malignant tumours was 0.791 and 0.801, respectively, and the AUC of peak time was high. The best cut-off point of miR-1469 in the diagnosis of liver malignant tumours was 0.88. The sensitivity, AUC and Youden index of combined diagnosis of contrast-enhanced ultrasound combined with mir-1469 were 74.46%, 0.912 and 0.640, respectively. Conclusion Low-dose contrast-enhanced ultrasound combined with serum miR-1469 can be used to diagnose benign and malignant liver tumours. The diagnostic efficiency is better than that of single diagnosis, and the clinical application value is higher.
- Contrast-enhanced ultrasound /
- MicroRNA-1469 /
- Liver tumours /
- Diagnosis

HTML全文

图 1 峰值强度、达峰时间诊断肝脏肿瘤良恶性的ROC曲线

Figure 1. ROC curve of peak intensity and peak time in diagnosis of benign and malignant liver tumors

下载: 全尺寸图片幻灯片

图 2 超声造影、miR-1469及其联合诊断肝脏肿瘤良恶性的ROC曲线

Figure 2. The ROC curve of ultrasonic imaging, miR - 1469 and its joint diagnosis of benign and malignant liver tumor

下载: 全尺寸图片幻灯片

表 1 2组肝脏肿瘤患者超声造影指标比较(x ±s)

Table 1. Comparison of contrast-enhanced ultrasound index in liver tumor patients between 2 groups(x ±s)

组别	例数	峰值强度(dB)	峰值加速时间(s)	达峰时间(s)	120 s回声强度(dB)
良性肿瘤组	50	127.84±14.59	21.15±4.06	60.28±6.52	33.55±5.56
恶性肿瘤组	53	186.36±18.14	19.87±3.12	40.75±4.87	31.47±5.95
t值		17.975	1.800	17.288	1.830
P值		＜0.001	0.075	＜0.001	0.070

下载: 导出CSV

表 2 3种诊断方案的诊断效能比较

Table 2. Comparison of diagnostic effectiveness of three diagnostic schemes

诊断方案	最佳截断点	灵敏度(%)	特异度(%)	AUC (95% CI)	约登指数
超声造影(达峰时间, s)	42.34	78.26	82.08	0.801(0.750~0.845)	0.603
miR-1469	0.88	76.91	71.54	0.780(0.738~0.827)	0.485
联合诊断		74.46	89.49	0.912(0.874~0.942)	0.640

下载: 导出CSV

参考文献(20)

[1]	TU H B, CHEN L H, LIN J L, et al. Liver cancer confirmation by contrast-enhanced ultrasound coupled with magnetic resonance imaging: case report of liver inflammation misdiagnosed as atypical liver cancer[J]. J Ultras Med, 2020, 39(7): 1453-1457. doi: 10.1002/jum.15233
[2]	LI B, LI B A, GUO T S, et al. Application value of mass spectrometry in the differentiation of benign and malignant liver tumors[J]. Med Sci Monit, 2017, 4(23): 1636-1644.
[3]	陈恩利, 楼俊晓, 王镇, 等. lncRNA GIHCG通过调节miR-429在原发性肝癌发生发展中的作用[J]. 中华全科医学, 2019, 17(5): 779-783. doi: 10.16766/j.cnki.issn.1674-4152.000790 CHEN E L, LOU J X, WANG Z, et al. Role of lncRNA GIHCG in the development of primary liver cancer by regulating miR-429[J]. Chinese Journal of General Practice, 2019, 17(5): 779-783. doi: 10.16766/j.cnki.issn.1674-4152.000790
[4]	于福盈, 王春光, 辛旺, 等. 超声造影联合血清学检测诊断肝脏良恶性肿瘤[J]. 肝脏, 2019, 24(2): 172-174. doi: 10.14000/j.cnki.issn.1008-1704.2019.02.021 YU F Y, WANG C G, XIN W, et al. Diagnosis of benign and malignant liver tumors by contrast-enhanced ultrasound combined with serology[J]. Chinese Hepatology, 2019, 24(2): 172-174. doi: 10.14000/j.cnki.issn.1008-1704.2019.02.021
[5]	ZHENG Q, ZHANG J C, WANG Z, et al. Assessment of angiogenesis in rabbit orthotropic liver tumors using three-dimensional dynamic contrast-enhanced ultrasound compared with two-dimensional DCE-US[J]. Jpn J Radiol, 2019, 37(10): 701-707. doi: 10.1007/s11604-019-00861-z
[6]	LIU J, WANG C F, LIU X Y, et al. Low expression of miR-1469 predicts disease progression and unfavorable post-surgical clinical outcomes in patients with esophageal squamous cell cancer[J]. Oncol Lett, 2017, 13(6): 4469-4474. doi: 10.3892/ol.2017.5957
[7]	LEE J H, SUH J H, KANG H J, et al. Tonicity-responsive enhancer-binding protein promotes stemness of liver cancer and cisplatin resistance[J]. EBio Med, 2020, 10(58): 102926. DOI: 10.1016/j.ebiom.2020.102926.
[8]	俞南松, 严培军, 郑媛媛, 等. 射频消融联合索拉非尼治疗中晚期肝癌对患者肝功能的影响及疗效分析[J]. 中华全科医学, 2018, 16(5): 754-756. doi: 10.16766/j.cnki.issn.1674-4152.000205 YU N S, YAN P J, ZHENG Y Y, et al. Effect of radiofrequency ablation combined with sorafenib on liver function in patients with advanced hepatic carcinoma[J]. Chinese Journal of General Practice, 2018, 16(5): 754-756. doi: 10.16766/j.cnki.issn.1674-4152.000205
[9]	MARRERO J A, KULIK L M, SIRLIN C B, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2018, 68(2): 723-750. doi: 10.1002/hep.29913
[10]	ZHANG Q, LOU Y, BAI X L, et al. Immunometabolism: a novel perspective of liver cancer microenvironment and its influence on tumor progression[J]. World J Gastroenterol, 2018, 24(31): 3500-3512. doi: 10.3748/wjg.v24.i31.3500
[11]	YIN J, QIU J J, QIAN W, et al. A radiomics signature to identify malignant and benign liver tumors on plain CT images[J]. J Xray Sci Technol, 2020, 28(4): 683-694.
[12]	BURENINA O Y, LAZAREVICH N L, KUSTOVA I F, et al. Panel of potential lncRNA biomarkers can distinguish various types of liver malignant and benign tumors[J]. J Cancer Res Clin Oncol, 2020, 147(1): 49-59.
[13]	杨小芳, 蔡春晓, 刘阳桦. 超声造影联合血清CEA, CA72-4对卵巢良恶性肿瘤鉴别诊断的价值[J]. 现代肿瘤医学, 2020, 28(9): 1508-1512. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL202009019.htm YANG X F, CAI C X, LIU Y Y. Value of contrast-enhanced ultrasound combined with serum CEA and CA72-4 in differential diagnosis of benign and malignant ovarian tumors[J]. Journal of Modern Oncology, 2020, 28(9): 1508-1512. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL202009019.htm
[14]	GONG E, PAULY J M, WINTERMARK M, et al. Deep learning enables reduced gadolinium dose for contrast-enhanced brain MRI[J]. J Magn Reson Imaging, 2018, 48(2): 330-340. doi: 10.1002/jmri.25970
[15]	HE D, CHATTERJEE A, FAN X, et al. Feasibility of dynamic contrast-enhanced magnetic resonance imaging using low-dose gadolinium: comparative performance with standard dose in prostate cancer diagnosis[J]. Invest Radiol, 2018, 53(10): 609-615. doi: 10.1097/RLI.0000000000000466
[16]	LAADER A, BEIDERRWELLEN K, KRAFF O, et al. Non-enhanced versus low-dose contrast-enhanced renal magnetic resonance angiography at 7 T: a feasibility study[J]. Acta Radiol, 2018, 59(3): 296-304. doi: 10.1177/0284185117718399
[17]	AlAMOUDI A A, ALNOURY A, GAD H. miRNA in tumour metabolism and why could it be the preferred pathway for energy reprograming[J]. Brief Funct Genomics, 2018, 17(3): 157-169. doi: 10.1093/bfgp/elx023
[18]	LIU J, WANG C F, LIU X Y, et al. Low expression of miR-1469 predicts disease progression and unfavorable post-surgical clinical outcomes in patients with esophageal squamous cell cancer[J]. Oncol Lett, 2017, 13(6): 4469-4474.
[19]	王宇锋, 朱怡凤, 殷国志. 肝细胞癌中microRNA-1469表达及其对肝癌细胞生物学行为的影响[J]. 新乡医学院学报, 2019, 36(9): 806-814. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYX201909003.htm WANG Y F, ZHU Y F, YIN G Z. Expression of microRNA-1469 and its function in hepatocellular carcinoma cells[J]. Journal of Xinxiang Medical University, 2019, 36(9): 806-814. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYX201909003.htm
[20]	闫珊玲, 卢强, 郑红, 等. 超声造影时间-强度曲线联合血清学检测在肝脏肿瘤良恶性鉴别诊断中的价值[J]. 实用医院临床杂志, 2018, 15(1): 39-42. https://www.cnki.com.cn/Article/CJFDTOTAL-YYLC201801013.htm YAN S L, LU Q, ZHENG H, et al. Clinical value of time-intensity curve of contrast-enhanced ultrasound combined with serologic tests in differential diagnosis of liver benign and malignant tumors[J]. Practical Journal of Clinical Medicine, 2018, 15(1): 39-42. https://www.cnki.com.cn/Article/CJFDTOTAL-YYLC201801013.htm